4 Healthcare Stock Stories for Weekend Investor Wellness

Eli Lilly and Company (NYSE:LLY): Current price $30.70

Lilly and Kowa Pharmaceuticals America have announced the results of a study evaluating the efficacy of Livalo (pitavastatin) 4 mg compared with pravastatin 40 mg in lowering low-density lipoprotein cholesterol in HIV-infected adults with high cholesterol, or dyslipidemia. The evaluation was created as a superiority trial for the primary endpoint, percent reduction in LDL-C, and evaluated HIV-infected adults with dyslipidemia,with and without viral Hepatitis B or C. The study achieved its primary endpoint.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LLY

Horizon Pharma (NASDAQ:HZNP): Current price $2.16

On Thursday, Horizon reported that the United Kingdom Medicines and Healthcare products Regulatory Agency has awarded marketing authorization for Duexis (ibuprofen/famotidine) for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who require regular treatment with high dose ibuprofen dosed three times a day, and who are at risk of developing non-steroidal anti-inflammatory drug associated gastric and/or duodenal ulcers. Horizon is looking to license rights to Duexis in Europe to one or more commercial partners.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

HZNP

Merck & Co. (NYSE:MRK): Current price $43

Merck announces the appointment of Roger M. Perlmutter, M.D., Ph.D., as executive vice president and president of Merck Research Laboratories, effective April 15. Perlmutter will succeed Peter S. Kim, Ph.D., who has served in the role since 2003.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

MRK
NeoStem (AMEX:NBS): Current price $0.59

The firm reported that it has won approval to continue the PreSERVE AMI Phase 2 clinical trial, subsequent to its second interim data and safety review by the Data Safety Monitoring Board. The trial of AMR-001 is a Phase 2, randomized, placebo controlled, double-blind study created to treat 160 patients and is cleared by the FDA to enroll up to 180 patients. AMR-001 is being studied for the prevention of major adverse cardiac events following acute myocardial infarction. Patient enrollment for the PreSERVE trial began in January 2012, and NeoStem expects the completion of enrollment in 2013 with initial data readout six to eight months later.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

NBS

Don’t Miss: Should American Workers Celebrate This News?